Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation

Executive Summary

Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.

You may also be interested in...



Ways And Means Drug Pricing Hearing Emphasizes Repetitive, Years-Old Questions

There was little on specific legislative proposals and a lot of time discussing broad questions that Congress has been asking for years about drug pricing.

Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments

State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.

Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach

Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions or else.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel